Kornimate/medical-research-clean huggingface dataset:
prostasomes as diagnostic tool for prostate cancer detection

Conditions: Prostate Cancer

Summary: prostate cancer is the most frequently diagnosed cancer among men over 50 years old in western societies, with an incidence that is steadily increasing in most countries. the current, most commonly used biomarker for prostate cancer is prostate specific antigen (psa), which has well known limitations in accuracy and requires additional testing. however, prostate cancer cells secrete exosomes, also known as prostasomes, which are only detectable in the blood of prostate cancer patients. the presence of prostasomes in the blood is in itself a prostate cancer diagnosis. however, the assay that has been designed for the purification of prostasomes requires additional testing for evaluating its robustness and usefulness in the clinical setting. additionally, the evaluation of the cargo of the purified prostasomes may provide more information on the nature of the prostate cancer, which may help develop a molecular assay for a prostate cancer liquid biopsy rather than a tissue biopsy. therefore, the purpose of this study is two-fold: a validation phase where the purification of prostasomes will be tested on plasma collected from prostate cancer patients and a molecular testing phase where the contents of the purified prostasomes will be evaluated on their ability to determine the grade of the prostate tumors. we will collaborate with dr. masood kamali-moghaddam at the uppsala university (department of immunology, genetics and pathology) for molecular assay processing.


Eligibility criteria:
inclusion criteria: * male * with elevated psa or patients with diagnosed prostate cancer * 18 years and older * willingness to participate in the study and compliance with protocol requirements * have not received any type of treatment for prostate cancer exclusion criteria: * patients with confirmed or suspected prostate cancer that have already received any type of treatment * patients with another primary cancer within the past five years of prostate cancer diagnosis. however, superficial skin cancers such as basal cell or squamous cell cancers would not exclude a patient.

Keywords: prostasomes, prostate cancer, biomarkers
study to assess accuracy of rapid mood screener in adult participants with unipolar major depressive disorder or bipolar 1 disorder in real world setting

Conditions: Bipolar I Disorder

Summary: bipolar i disorder (bp1)is a severe chronic mood disorder characterized by manic and depression. bp1 has high probability of being misunderstood as unipolar major depressive disorder (mdd). the purpose of this study is to confirm rapid mood screener (rms) effectively classifies participants with bp1. rapid mood screener (rms) is a brief 6-item clinician-administered checklist, in which a participant's endorsement of four or more questions should trigger further clinical evaluation for bp1. approximately 404 participants (303 with confirmed unipolar mdd and 101 with confirmed bp1) will be enrolled in the united states. participants will be answering rms questionnaire and accuracy will be measured against mini-international neuropsychiatric interview (mini) interview.


Eligibility criteria:
inclusion criteria: * presenting to provider with primary complaint of new or continuing depressive symptoms. * may be treatment naïve even if not in their first depressive episode. * meets one of the following criteria: * previously treated and currently off medication. * currently using an antidepressant, atypical antipsychotic for mood disorder, or mood stabilizer. exclusion criteria: * hospitalized or admitted to the emergency room due to mental health issues in the past 30 days. * currently experiencing a manic episode. * history of schizophrenia or depression due to another psychotic disorder or a medical, organic, or drug-induced cause or a neurocognitive disorder (dementia/delirium) (as defined by diagnostic and statistical manual of mental disorders \[dsm-v\] criteria). * participant did not provide informed consent.

Keywords: bipolar i disorder (bp1) unipolar major depressive disorder (mdd) rapid mood screener (rms)
gilteritinib in combination with venetoclax and azacitidine for aml patients with flt3 mutations ineligible for intensive treatment

Conditions: AML - Acute Myeloid Leukemia

Summary: explore the best tolerable and efficacious dose of gilteritinib when combined with standard treatment with venetoclax and azacitidine in aml patients with flt3 mutations which are ineligible for intensive chemotherapy


Eligibility criteria:
main inclusion criteria: * newly diagnosed aml (according to who 2022 or icc 2022 criteria) with a minimum bm blast count of \>=20%, excluding apl * flt3 mutation at initial diagnosis * ineligibility of standard induction chemotherapy * pre-treatment with approved combination of venetoclax + azacitidine (one cycle only) main exclusion criteria: * r/r aml * previous treatment for aml (except hu and/or one cycle ven+aza according to soc) * previous treatment with gilteritinib * known active cns involvement * qtcf \>450 ms or long qt syndrome at screening * treatment with concomitant strong cyp3a inducers or st. john's wort
the diagnostic efficacy of glutamine synthetaseand bclaf1in early diagosis of hepatocellular carcinoma in cirrhotic patients

Conditions: Hepatocellular Carcinoma

Summary: hepatocellular carcinoma (hcc) is the most prominent kind of liver cancer, accounting for 85% of primary liver malignancies. it is a very aggressive tumor, having a terrible prognosis and poor survival rate hcc is ranked as the sixth most common type of cancer and the third leading cause of cancer-related mortalities world wide. hcc incidences arise in complications associated with chronic liver disease like cirrhosis, endemic hepatitis b virus (hbv)/hepatitis c virus (hcv) infections, non alcoholic fatty liver disease (nafld), and alcohol-related liver disease (torre, 2015).


Eligibility criteria:
inclusion criteria: * a total 90 adult patients with liver cirrhosis attending the outpatient clinic or in patient section of the department of tropical medicine and gastroenterology at sohag university hospital will be included in the study. patients will be divided into two groups: group i: the study group will include 45 patients diagnosed with liver cirrhosis with absence of hepatic focal lesion as control group. cirrhosis will be determined according to clinical , sereological ,radiological findings. group ii: the study group will include 45 patient with hcc on top of liver cirrhosis .all causes of liver cirrhosis will be accepted .hcc will be assessed by triphasic ct or mri or histological validation .in these group we will take patients with liver cirrhosis with early hepatocellular carcinoma that defined as tumors smaller than 3cm and three or fewer in number at stage a according to bclc staging also sometimes it includes solitary tumors up to 5 cm in size as defined in the milan criteria. both very early and early stage tumors are relatively small but both are hyper vascular in arterial phase. exclusion criteria: 1. non cirrhotic patients. 2. patients with distant metastasis. 3. patients aged below18 years. 4. patients with other malignancy rather than hcc. 5. patients with late stage of hcc.
predictive tools in head and neck cancer patients undergoing radiotherapy

Conditions: Head and Neck Cancers; Head and Neck Cancers - Nasopharyngeal; Oral Cavity Cancer; Oropharyngeal Cancers; Radiotherapy Side Effects

Summary: the ithaca study aims to improve the treatment of head and neck cancer by developing a predictive tool that helps doctors personalize care for each patient. this tool uses information such as medical history, imaging, and radiotherapy data to predict the risk of cancer recurrence, overall survival, and the likelihood of side effects. patients with head and neck cancer face significant challenges, including managing the side effects of treatments like radiotherapy. by tailoring treatment schedules and doses, and using advanced imaging techniques, we hope to reduce complications and improve survival outcomes. the study is designed to help doctors choose the best treatment for each patient, while minimizing the side effects that impact important functions like swallowing and breathing. patients participating in the study will have their medical data collected, including: tumor characteristics (size, location, stage). treatment details (radiotherapy and chemotherapy). imaging information using tools like pet-ct and mri to track the response to treatment and detect any signs of cancer recurrence. side effects and overall health data. this information will be used to develop and test a new model that predicts outcomes for each patient based on their unique data. the study includes adults (18 years and older) diagnosed with head and neck cancer, who are undergoing or have completed radiotherapy. patients will be followed over time to monitor their response to treatment and any side effects.


Eligibility criteria:
inclusion criteria participants must meet all of the following criteria: * diagnosis: confirmed head and neck cancer, including cancers of the oropharynx, larynx, hypopharynx, nasopharynx, salivary gland, unknown head and neck primary or oral cavity. * age: 18 years or older. * treatment: undergoing or scheduled to undergo radiotherapy or chemoradiotherapy as part of their treatment exclusion criteria participants will be excluded if they meet any of the following criteria: * pregnancy: pregnant or breastfeeding women. * non-compliance: patients unwilling or unable to comply with study procedures and follow-ups.

Keywords: head and neck cancer radiotherapy chemoradiotherapy radiomics personalized treatment dosiomics
non-invasive ventilation via a helmet device for patients respiratory failure

Conditions: Acute Respiratory Distress Syndrome; Shock; Ventilatory Failure; Cardiogenic Pulmonary Edema

Summary: the objective of our study is to evaluate the efficacy of helmet ventilation as compared with face mask in patients with respiratory failure.

respiratory failure is often treated with endotracheal intubation and mechanical ventilation. although, the institution of mechanical ventilation is considered life saving, the associated complications of tracheal stenosis, ventilator associated pneumonia, barotrauma , and neuromuscular weakness are not without considerable morbidity and mortality. non-invasive ventilation has demonstrated significant benefit in patients with hypercapnic respiratory failure from copd, acute cardiogenic pulmonary edema, and hypoxemic respiratory failure in immunocompromised patients. despite the advantages of non-invasive ventilation via facemask, some patients fail because of mask intolerance and severity of disease. further limitation to facemask non-invasive ventilation is that the seal integrity is lost when higher pressures are required. unfortunately, certain types of respiratory failure such as that due to hypoxemia or shock may require such higher pressures. in an attempt to improve patient tolerability and deliver higher pressures, a transparent helmet has been proposed as a novel interface for non-invasive ventilation. it encloses the entire head and neck of the patient. the design of the helmet confers some important advantages: 1) the transparency allows the patient to interact with the environment; 2) the lack of contact to the face lowers the risk of skin necrosis; 3) the helmet avoids problems of leaking with higher airway pressures that are seen with the face mask; 4) it can be applied to any patient regardless of facial contour.

Eligibility criteria:
inclusion criteria: * patients aged ≥18 years of age who require noninvasive ventilation via facemask for \>8hours * intact airway protective gag reflex * able to follow instructions exclusion criteria: * cardiopulmonary arrest * glasgow coma scale \<8 * absence of airway protective gag reflex * elevated intracranial pressure * tracheostomy * upper airway obstruction * pregnancy. * patients who refuse to undergo endotracheal intubation, whatever the initial therapeutic approach

Keywords: noninvasive ventilation acute hypoxemic respiratory failure acute respiratory distress syndrome shock
prevention chemotherapy induced mucositis by zinc sulfate

Conditions: Mucositis; Bone Marrow Transplantation

Summary: in this double blinded randomized study we evaluate effect of zinc sulfate for prevention mucositis due to high dose chemotherapy in the patients undergoing bone marrow transplantation whose received busulfan and/or cyclophosphamide. patients randomized in two groups: intervention and control with balanced block randomization method. intervention group received zinc sulfate immediately after start conditioning regimen and continued for two weeks. control group received placebo at the same manner. prevalence and severity of mucositis will be compared in two groups.


Eligibility criteria:
inclusion criteria: * patient undergoing bone marrow transplantation * signed informed consent exclusion criteria: * unable take drug (or placebo) orally

Keywords: mucositis bone marrow transplantation bmt hsct
design of a model to study functionality of the trigeminal nerve in relation to controlled nasal fractures

Conditions: Fracture of Nasal Bones, Sequela

Summary: the primary aim of the study is to create a model; in order to examine the effects of neural trauma in patients that are healthy individuals, induced by controlled nasal fractures during rhinoplasty, and the regeneration process in the weeks/months that follow. this study includes monitoring of subjective nasal symptoms with a visual analogue scale (vas) score, peak nasal inspiratory flow (pnif) measurements, collection of nasal secretions and nasal provocation (response to capsaicin and cold dry air (cda) exposure).

the investigators will set up a prospective mono-center study. the investigators will utilize objective and subjective parameters in order to assess trigeminal nerve function at the level of the nasal mucosa before and after septorhinoplasty (as a model of controlled nasal fractures). the subjective parameters involve a visual analogue scale (vas) score for each individual nasal symptom (nasal obstruction, facial pain/pressure, headache, rhinorrhea, sneezing, pruritus, post nasal drip, and loss of smell). an objective assessment includes measurement of pnif (peak nasal inspiratory flow), the presence of neuropeptides in nasal secretions, (by introducing merocels and removing them 5 minutes later), short cold dry air (cda) provocation and capsaicin provocation with subsequent measurements of pnif and vas scores and neuropeptides.

Eligibility criteria:
inclusion criteria: 1. patients undergoing septorhinoplasty, with planned bilateral osteotomies 2. no rhinological symptoms/complaints (rhinorrhea, sneezing, itchiness, nasal obstruction) 3. age \> 18 and \< 65 years 4. written informed consent 5. willingness to adhere to visit schedules 6. adequate contraceptive precautions in female patients with childbearing potential exclusion criteria: 1. age \ 65 years 2. patients with nasal symptoms at baseline, defined as having more than 2,5 on vas score for individual nasal symptoms related to mucosal pathology 3. nasal endoscopic signs of inflammatory pathology (rhinitis, rhinosinusitis with/without nasal polyps) 4. use of systemic steroid treatment, intranasal steroid treatment, oral leukotriene antagonists or long acting antihistamines? 5. asthma 6. pregnancy or breastfeeding 7. any disorder of which might compromise the ability of a patient to give truly informed consent for participation in this study. 8. enrollment in other investigational drug trial(s) or is receiving other investigational agent(s) for any other medical condition. 9. contra-indications for local anaesthesia (cocaine 5%) 10. smoking 11. systemic disease with lesions in ent domain 12. malignancies or severe comorbidity
a quality improvement plan for hypertension control

Conditions: Hypertension

Summary: the study hypothesis is that the implementation of a plan for quality improvement at the primary care health teams taking care of hypertensive patients, will increase the level of blood pressure control among those patients.

the study is to compare the results on the hypertension control between two groups of primary health care teams. the intervention group will undertake a quality improvement plan for hypertension control, in which the following aspects will be included in the intervention: specific training programme on how to diagnose hypertension , and measure blood pressure correctly to send feed back information to primary care health professionals about poorly controlled hypertensive patients an audit will be performed, every 6 months, to see the adhesion to the recommended clinical guidelines , and the information will be diffused among the participant primary health care professionals each participant primary health care team will have a designated reference person, that will provide support on any doubts on the programme implementation. the non intervention group will follow hypertensive patients following the same clinical practice guide as the intervention group, with no intervention on the primary health care professionals

Eligibility criteria:
inclusion criteria: * patients diagnosed with hypertension before january 1st, 2006 * patients assigned at the primary health team participating, and with clinical electronic records exclusion criteria: * patients diagnosed with hypertension after january 1st, 2006 * patients under 18 years of age * patients with a diastolic blood pressure higher than systolic blood pressure as recorded in the clinical records

Keywords: hypertension intervention primary care quality improvement
efficacy of atomoxetine on psychosocial function of children and adolescents with attention-deficit/hyperactivity disorder (adhd)

Conditions: Attention Deficit Disorder With Hyperactivity

Summary: this study aims to assess the effectiveness of atomoxetine on psychosocial functioning and emotional well being of children and adolescents with adhd and to evaluate whether and in what measure the presence of comorbid conditions (internalizing and externalizing disorders) influences atomoxetine's ability to improve the quality of life of adhd subjects.


Eligibility criteria:
inclusion criteria: * child or adolescent patients, male or female outpatients, who are at least 6 years of age, but must not yet have reached their 16th birthday prior to visit 1, when informed consent is obtained * patients must meet diagnostic and statistical manual of mental disorders fourth edition (dsm-iv) diagnostic criteria for adhd (any subtype) and score at least 1.5 standard deviations above the age norm for their diagnostic subtype using published norms for the swanson, nolan and pelham questionnaire: attention-deficit/hyperactivity disorder subscale (snap-iv adhd subscale) score at both visit 1 and 2 * laboratory results, including serum chemistries, hematology, and urinalysis, must show no clinically significant abnormalities (clinically significant is defined as laboratory values requiring acute medical intervention, indicating a serious medical illness, or requiring further medical evaluation in the judgment of the investigator) * an electrocardiogram (ecg) must be performed to exclude cardiac diseases at the baseline/screening visit and the results must be reviewed by the investigator at visit 2 prior to dispensing of study material * patients and parents have been judged by the investigator to be reliable to keep appointments for clinic visits and all tests, including venipuncture, and examinations required by the protocol. exclusion criteria: * patients who have a documented history of bipolar i or ii disorder, any history of psychosis or pervasive development disorder * patients with a history of any seizure disorder (other than febrile seizures) or patients who have taken (or are currently taking) anticonvulsants for seizure control are not eligible to participate * patients at serious suicidal risk as assessed by the investigator * patients with significant cardiovascular disease or other conditions that could be aggravated by an increased heart rate or increased blood pressure * patients who have any medical condition that would increase sympathetic nervous system activity markedly (for example, catecholamine-secreting neural tumor), or who are taking a medication on a daily basis (for example, albuterol, inhalation aerosols, pseudoephedrine), that has sympathomimetic activity. such medications can be taken on an as-needed basis
comparison of two ventilation modes with laryngeal mask airway guardian

Conditions: Gynecologic Disease

Summary: the purpose of this study is to compare volume- and pressure- controlled ventilation with laryngeal mask airway guardian in obese patients undergoing laparoscopic gynecologic surgery in terms of ventilatory efficacy, airway leak pressure (airway protection), ease-of-use and complications.

the guardian laryngeal mask (ultimate medical pty ltd, richmond, vic, australia) is a new silicone-based single-use extraglottic airway device that forms a seal with the glottis for ventilation and with the hypopharynx for airway protection, and provides a gastric drainage port. the aim of the following perspective, randomized, blind trial study id to compare how the volume-controlled ventilation and pressure-controlled ventilation modes using the laryngeal mask guardian affect the pulmonary mechanics, the gas exchange and the cardiovascular responses particularly in obese patients undergoing gynecological laparoscopy.

Eligibility criteria:
inclusion criteria: * ambulatory patients scheduled to undergo laparoscopic gynecologic surgery under a short general paralysed anesthesia of less than 2 hours (asa physical status i-ii) * 18 to 65 years of age * a body mass index \<40 kg • m-2 exclusion criteria: * difficult airway * recent history of upper respiratory tract infection and sore throats * a history of esophageal reflux disease * kinesia patients * inability to understand the study information sheet and provide a written consent to take part in the study

Keywords: volume controlled ventilation pressure controlled ventilation